Floatz logo

Surufatinib

Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

HutchmedSmall moleculePhase 1/2Active
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

103 Active assets in the Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) cohort.

Asset / SponsorPhaseRating
Palbociclib
Brown University
Phase 2BB
FILGRASTIM
University of California, Irvine
Phase 3BB
Inno-206
GI Innovation, Inc.
Phase 3BB
Eloxatin
OHSU Knight Cancer Institute
Phase 2BB
Cyclophosphamide
St. Jude Children's Research Hospital
Phase 2BB

View all 50 →

Same molecule, other indications

Surufatinib is also rated in:

malignant pancreatic neoplasmDormant
BB
Indicative ·
65 / 100
View asset →
neuroendocrine neoplasmDormant
BB
Indicative ·
64 / 100
View asset →
colorectal cancerDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →